FR3092581A1 - Formes cristallines d'un inhibiteur de jak2 - Google Patents

Formes cristallines d'un inhibiteur de jak2 Download PDF

Info

Publication number
FR3092581A1
FR3092581A1 FR1902018A FR1902018A FR3092581A1 FR 3092581 A1 FR3092581 A1 FR 3092581A1 FR 1902018 A FR1902018 A FR 1902018A FR 1902018 A FR1902018 A FR 1902018A FR 3092581 A1 FR3092581 A1 FR 3092581A1
Authority
FR
France
Prior art keywords
crystalline form
degrees
compound
form according
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR1902018A
Other languages
English (en)
French (fr)
Inventor
Benoit ROBERT
Pascal Billot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Priority to FR1902018A priority Critical patent/FR3092581A1/fr
Priority to EP20756422.0A priority patent/EP3927704A4/en
Priority to CN202080027762.4A priority patent/CN114026088A/zh
Priority to AU2020221796A priority patent/AU2020221796A1/en
Priority to MX2021009423A priority patent/MX2021009423A/es
Priority to JP2021547092A priority patent/JP2022520083A/ja
Priority to EA202192237A priority patent/EA202192237A1/ru
Priority to SG11202108607QA priority patent/SG11202108607QA/en
Priority to BR112021015318-7A priority patent/BR112021015318A2/pt
Priority to KR1020217029156A priority patent/KR20210148110A/ko
Priority to US17/430,148 priority patent/US20220332706A1/en
Priority to PCT/US2020/017764 priority patent/WO2020167844A1/en
Publication of FR3092581A1 publication Critical patent/FR3092581A1/fr
Priority to IL285427A priority patent/IL285427A/en
Priority to JP2024212168A priority patent/JP2025032217A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1902018A 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2 Pending FR3092581A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
SG11202108607QA SG11202108607QA (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor
BR112021015318-7A BR112021015318A2 (pt) 2019-02-12 2020-02-11 Formas cristalinas de um inibidor de jak2
AU2020221796A AU2020221796A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a JAK2 inhibitor
MX2021009423A MX2021009423A (es) 2019-02-12 2020-02-11 Formas cristalinas de un inhibidor de la janocinasa 2 (jak2).
JP2021547092A JP2022520083A (ja) 2019-02-12 2020-02-11 Ｊａｋ２阻害剤の結晶形態
EA202192237A EA202192237A1 (ru) 2019-02-12 2020-02-11 Кристаллические формы ингибитора jak2
EP20756422.0A EP3927704A4 (en) 2019-02-12 2020-02-11 CRYSTALLINE FORMS OF A JAK2 INHIBITOR
CN202080027762.4A CN114026088A (zh) 2019-02-12 2020-02-11 Jak2抑制剂的结晶形式
KR1020217029156A KR20210148110A (ko) 2019-02-12 2020-02-11 Jak2 저해제의 결정 형태
US17/430,148 US20220332706A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor
IL285427A IL285427A (en) 2019-02-12 2021-08-06 Crystal forms of jak2 inhibitor
JP2024212168A JP2025032217A (ja) 2019-02-12 2024-12-05 Ｊａｋ２阻害剤の結晶形態

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1902018 2019-02-12
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2

Publications (1)

Publication Number Publication Date
FR3092581A1 true FR3092581A1 (fr) 2020-08-14

Family

ID=68281482

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1902018A Pending FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2

Country Status (13)

Country Link
US (1) US20220332706A1 (https=)
EP (1) EP3927704A4 (https=)
JP (2) JP2022520083A (https=)
KR (1) KR20210148110A (https=)
CN (1) CN114026088A (https=)
AU (1) AU2020221796A1 (https=)
BR (1) BR112021015318A2 (https=)
EA (1) EA202192237A1 (https=)
FR (1) FR3092581A1 (https=)
IL (1) IL285427A (https=)
MX (1) MX2021009423A (https=)
SG (1) SG11202108607QA (https=)
WO (1) WO2020167844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
US12559463B2 (en) * 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2012060847A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040804B2 (en) * 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2012060847A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5 *

Also Published As

Publication number Publication date
CN114026088A (zh) 2022-02-08
SG11202108607QA (en) 2021-09-29
JP2022520083A (ja) 2022-03-28
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
JP2025032217A (ja) 2025-03-11
MX2021009423A (es) 2021-11-17
AU2020221796A1 (en) 2021-08-12
IL285427A (en) 2021-09-30
KR20210148110A (ko) 2021-12-07
EP3927704A4 (en) 2022-12-28
US20220332706A1 (en) 2022-10-20
EP3927704A1 (en) 2021-12-29
EA202192237A1 (ru) 2021-12-14

Similar Documents

Publication Publication Date Title
EP3122753A2 (en) Ibrutinib solid forms and production process therefor
JP2014530805A (ja) アジルサルタンの結晶形並びにその製造及び使用
JP2025094218A (ja) Ｊａｋ２阻害剤の結晶形態
MX2012015200A (es) Polimorfos de osi-906.
AU2020348089B2 (en) Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same
JP2025032217A (ja) Ｊａｋ２阻害剤の結晶形態
KR20130095751A (ko) 4-[-2-[[5-메틸-1-(2-나프탈레닐)-1h-피라졸-3-일]옥시]에틸]모르폴린 하이드로클로라이드 무정형 고체 형태
KR20250007508A (ko) 디하이드로오로테이트 탈수소효소(dhod) 억제제의 다형체
TWI567077B (zh) （１ｒ，４ｒ）－６’－氟－Ｎ，Ｎ－二甲基－４－苯基－４’，９’－二氫－３’Ｈ－螺－［環己烷－１，１’－吡喃並－［３，４，ｂ］吲哚］－４－胺鹽酸鹽之固體形式
TW202014412A (zh) 賽度替尼(cerdulatinib)之固體型式
TWI758287B (zh) 一種鈉依賴性葡萄糖共轉運蛋白抑制劑的胺溶劑合物及其製備方法和應用
US20220372024A1 (en) Crystalline forms of entrectinib
US20110165202A1 (en) Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
US10934260B2 (en) Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
US7777049B2 (en) Crystalline forms of Rizatriptan benzoate
RU2782068C2 (ru) Кристаллические соли и полиморфы антагониста p2x3
CN112543634A (zh) Ebna1抑制剂晶体形式及其制备和使用方法
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
TW202527943A (zh) 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式
US9012459B2 (en) Monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)-piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, preparation, and pharmaceutical composition thereof
WO2017032705A1 (en) Crystalline form of omarigliptin
HK40110791B (zh) N-(苯甲醯基)-苯丙氨酸类化合物的晶体及其药物组合物、制备方法和用途
HK40110791A (zh) N-(苯甲醯基)-苯丙氨酸类化合物的晶体及其药物组合物、制备方法和用途
FR2897614A1 (fr) Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations
HK40050819A (en) Ebna1 inhibitor crystalline forms, and methods of preparing and using same

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200814